Share
Click the heart to show your support of this pledge.
405
Latest News

Johnson & Johnson Signs a Historic Pledge to Uphold the Integrity of the Scientific Process in Developing an Investigational COVID-19 Vaccine

Share
Click the heart to show your support of this pledge.
405
In signing the pledge, we are joining eight other biopharmaceutical companies working on vaccine research and development in making the safety and well-being of vaccinated individuals our top priority.
Today's Top Reads Close

Today Johnson & Johnson is announcing that we, alongside eight other companies working on investigational COVID-19 vaccines, are signing a #WeStandWithScience pledge committed to upholding the integrity of the scientific process as we work towards potential global regulatory filings and approvals of the first vaccines for COVID-19.

In signing the pledge, Johnson & Johnson, AstraZeneca, BioNTech, GlaxoSmithKline, Merck, Moderna, Inc., Novavax, Inc., Pfizer Inc. and Sanofi are underscoring a united commitment to develop and test potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles regarding the conduct of our clinical trials and the rigor of our manufacturing processes.

As part of the pledge, the companies will continue to make the safety and well-being of vaccinated individuals their top priority, as well as work to ensure a sufficient supply and range of vaccine options, including those suitable for global access.

The companies also pledge to only submit their vaccines for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet the requirements of expert regulatory authorities.

To read more about the pledge, and why we believe rigorous science and safety must be the priority in vaccine development, go here.

Click the heart to show your support of this pledge.
405
Live Video Series
The Road to a Vaccine
In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.
Season 2, Episode 9
Experts Weigh In On COVID-19 Testing, Vaccine Trials and More
Lisa Ling speaks with Dr. Paul Stoffels on the latest coronavirus vaccine developments. Dr. Cato Laurencin discusses why it’s critical to have diversity in clinical trials. Plus, news on possible breakthroughs in COVID-19 diagnostic testing.

More from Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue